- September 2016
Freddie Hamdy on the effectiveness of treatments for prostate cancer.
- August 2016
Moshe Oren discusses the effects of the microenvironment on cancer cells.
- July 2016
Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
- June 2016
Key advances in clinical trials.
- May 2016
Mark Lemmon on the underlying biochemistry of cancer.
- April 2016
Roger Stupp on using alternating electric fields as treatment.
- March 2016
Charlotte Vrinten on public perception of deaths from cancer.
- February 2016
Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
- December 2015/January 2016
Nazneen Rahman on germline genetic screening in ovarian cancer.
- November 2015
Caroline Robert on new developments in immunotherapy.
- October 2015
Milena Sant on the latest results from the EUROCARE study.
EJC News Focus – October 2013
'New ways of learning are needed' as personalised medicine enters routine practice
Prospective observational registries, which record every clinical encounter with every patient, are going to be the way to continue progress in our understanding of cancer, according to Richard L Schilsky, Chief Medical Officer of the American Society of Clinical Oncology (ASCO).
Genetic characterisation has led to cancers which were traditionally considered common becoming instead a collection of rare diseases. It means that there are now too many cancers, too many drugs in development and not enough patients, time or money to study everything by doing clinical trials, he says.
In this month's EJC News Focus, Schilsky tells Helen Saul that as personalised medicine enters the clinic, changes are needed – and are happening – in research, development and the regulation of new cancer drugs.